Patents by Inventor Deliang Zhou
Deliang Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240137585Abstract: In some embodiments, a method sends a set of first requests for a set of first segments of a video in a playback session. A first protocol from a plurality of protocols is specified in at least one of the set of first requests. The set of first segments is received. The method determines whether to switch from using the first protocol to a second protocol in the playback session based on receiving the set of first segments. When switching to the second protocol, the method sends a second request in the playback session, wherein the second request indicates the second protocol is to be used to send a second segment of the video.Type: ApplicationFiled: January 2, 2024Publication date: April 25, 2024Applicant: HULU, LLCInventors: Tongyu Dai, Lan Xie, Wenhao Zhang, Deliang Fu, Chao Li, Qiang She, Yuting Gui, Yicheng Liu, Yanping Zhou, Xizhi Xu
-
Patent number: 8927009Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: December 21, 2010Date of Patent: January 6, 2015Assignee: AbbVie Inc.Inventors: Ping Tong, Deliang Zhou, Geoff G. Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
-
Patent number: 8728516Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: April 29, 2010Date of Patent: May 20, 2014Assignee: AbbVie Inc.Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Geoff G. Z. Zhang, Deliang Zhou
-
Patent number: 8362013Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: April 29, 2010Date of Patent: January 29, 2013Assignee: AbbVie Inc.Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G. Z. Zhang, Deliang Zhou
-
Publication number: 20110159085Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: December 21, 2010Publication date: June 30, 2011Applicant: ABBOTT LABORATORIESInventors: Ping Tong, Deliang Zhou, Geoff G.Z. Zhang, Katherine R. Heemstra, Cristina M. Fischer, Nathaniel D. Catron, Eric A. Schmitt, Yeshwant D. Sanzgiri
-
Publication number: 20100305125Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: December 2, 2010Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G.Z. Zhang, Deliang Zhou
-
Publication number: 20100297194Abstract: An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 25, 2010Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Rajeev Gokhale, Anthony R. Haight, Katherine Heemstra, David Hill, Martin Knobloch, Drazen Kostelac, Justin S. Lafountaine, Yanxia Li, Bernd Liepold, Kennan Marsh, Jonathan M. Miller, Claudia Packhaeuser, Yeshwant D. Sanzgiri, Eric A. Schmitt, Yi Shi, Norbert Steiger, Ping Tong, Huailiang Wu, Geoff G.Z. Zhang, Deliang Zhou
-
Publication number: 20100280031Abstract: An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Paul David, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Kennan Marsh, Peter Mayer, Vitaly Rubin, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Deliang Zhou
-
Publication number: 20100278905Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Geoff G. Z. Zhang, Deliang Zhou
-
Publication number: 20100278921Abstract: An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Inventors: Cristina M. Fischer, Rajeev Gokhale, Katherine Heemstra, David Hill, Kennan Marsh, Eric A. Schmitt, Yi Shi, Ping Tong, Deliang Zhou